Prevention and Treatment of liver cancer patients Shuganjianpi TACE clinical analysis of liver injury after.doc

 PAGE \* MERGEFORMAT 9 Prevention and Treatment of liver cancer patients Shuganjianpi TACE clinical analysis of liver injury after Of: Zhang Peng Liu Xiufang Zhaozeng Hu Cheng-Yun Li Luo book [Keywords:] liver TACE liver spleen Liver Act of liver functional reserve January 2005 -2007 in January, the Court of 69 oncology patients receiving hepatic arterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma treated by Shuganjianpi the prevention and treatment of liver injury, and achieved good results, are reported below. 1 Materials and Methods 1.1 Case selection criteria ① All cases were B-, liver enhanced CT with alpha-fetoprotein (AFP) or needle liver biopsy confirmed, ② inoperable patients or patients refusing surgery, ③ liver function Child A ~ B-class classification, ④ portal vein No thrombosis, ⑤ no significant portal hypertension, ⑥ no serious heart, lung, renal insufficiency, Karnofsky score of 70 or above, ⑦ expected survival more than 3 months. 1.2 General Information According to lt;”A New Specification for diagnosis and treatment of common malignant tumors? Primary liver cancer volumesgt;gt; [1] diagnostic criteria and clinical staging criteria, 69 patients hospitalized patients were randomly divided into 2 groups. Treatment group 35 cases, including 30 males 5 females, average age 48 years, Ⅱ of 29 cases, Ⅲ 6 cases. the control group of 34 patients, 29 males and 5 females, mean age 46 years, Ⅱ of 28 cases, Ⅲ .2 group of 6 patients age, gender, disease and so no significant difference between comparable. 1.3 Treatment 1.3.1 the control group Seldinger method used by patients with femoral artery, the first catheter into the celiac artery for selective digital subtraction, the tumor location, size, type, and the blood supply after superselective catheterization to the hepatic artery or left hepatic artery. diluted before doxorubicin injection 30 mg, mitomycin 10 mg, fluorouracil, 1 g, after the